A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract

cited authors

  • Abida, Wassim; Bradley, Thomas Paul; Rezazadeh, Arash; Karsh, Lawrence Ivan; Ross, Ashley; Saltzstein, Daniel; Argon, Evren Kocabas; Hamlett, Anthony; Tang, Jeanie; Adib, Deyaa

authors

Publication Date

  • February 20, 2020

webpage

published in

category

volume

  • 38

issue

  • 6